Publication: A Mechanistic Understanding of Axon Degeneration in Chemotherapy-Induced Peripheral Neuropathy
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media S.A.
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Fukuda, Yusuke, Yihang Li, and Rosalind A. Segal. 2017. “A Mechanistic Understanding of Axon Degeneration in Chemotherapy-Induced Peripheral Neuropathy.” Frontiers in Neuroscience 11 (1): 481. doi:10.3389/fnins.2017.00481. http://dx.doi.org/10.3389/fnins.2017.00481.
Research Data
Abstract
Chemotherapeutic agents cause many short and long term toxic side effects to peripheral nervous system (PNS) that drastically alter quality of life. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and enduring disorder caused by several anti-neoplastic agents. CIPN typically presents with neuropathic pain, numbness of distal extremities, and/or oversensitivity to thermal or mechanical stimuli. This adverse side effect often requires a reduction in chemotherapy dosage or even discontinuation of treatment. Currently there are no effective treatment options for CIPN. While the underlying mechanisms for CIPN are not understood, current data identify a “dying back” axon degeneration of distal nerve endings as the major pathology in this disorder. Therefore, mechanistic understanding of axon degeneration will provide insights into the pathway and molecular players responsible for CIPN. Here, we review recent findings that expand our understanding of the pathogenesis of CIPN and discuss pathways that may be shared with the axonal degeneration that occurs during developmental axon pruning and during injury-induced Wallerian degeneration. These mechanistic insights provide new avenues for development of therapies to prevent or treat CIPN.
Description
Other Available Sources
Keywords
Review, axon, chemotherapy, CIPN, degeneration, DRG, neuropathy, sensory neuron, Wallerian
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service